IL1B and Venous thrombosis: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) demonstrated that targeting interleukin-1β (IL-1β) using canakinumabcan could significantly reduce the incidences of cardiovascular events [150,151,152].